VLX1570

Research use only, not for human use.

VLX1570 is a small molecule b-AP15 analog that fucttion as proteasome deubiquitinase inhibitor with IC50 of 10 uM.

VLX1570 is a small molecule b-AP15 analog that fucttion as proteasome deubiquitinase inhibitor with IC50 of 10 uM, interacts at the active sites of the proteasome DUBs USP14 and UCHL5; demonstrates cytotoxicity in survival assays in HCT116 colon cancer cells with IC50 of 0.58 uM, shows no inhibitory activity on a panel of recombinant non-proteasome DUBs, recombinant kinases, or caspase-3; decreases cell viability in chemotherapy resistant endometrial cancer cells consistent with cell cycle arrest and caspase-3 mediated apoptosis; decreases tumor burden and prolongs survival in WM-xenografted mice.Blood Cancer Phase 2 Clinical(In Vitro):VLX1570 inhibits USP14 and UCHL5 activity of 19S regulatory particles, and the inhibition of USP14 is more pronounced. VLX1570 (1 μM) shows inhibitory activity against USP14 in KMS-11 myeloma cells. VLX1570 exhibits an IC50 of 0.58 μM on HCT116 cells. VLX1570 binds to recombinant USP14 with Kd of 1.5-18?μM using two different sources of recombinant protein, and the Kd for recombinant UCHL5 is higher (14-18?μM) compared to that of USP14. VLX1570 has potent antiproliferative activities on multiple myeloma cells, with IC50s of 43?±?2 nM, 74?±?2 nM, 126?±?3 nM, and 191?±?1 nM for KMS-11, RPMI8226, OPM-2, and OPM-2-BZR cells, respectively. VLX1570 suppresses the viability of BCWM.1 cells, with an EC50 of 20.22?nM. VLX1570 (100, 250, 500 nM) induces significant apoptosis by 12?h in a dose-dependent manner in all Waldenstrom macroglobulinemia (WM) cell lines tested, including BCWM.1/IR (IR) and BCWM.1/BR (BR) subclones. VLX1570 (100, 250, 500 nM) also causes ER stress machinery and mitochondrial damage in WM cells. VLX1570 (250?nM) downregulates BCR-signalosome components and their end effectors, as well as CXCR4 expression in WM cells.(In Vivo):VLX1570 (3?mg/kg) significantly decreases tumor growth in mice bearing KMS-11 multiple myeloma cells. VLX1570 (4.4?mg/kg, i.p.) markedly suppresses tumor growth, without obvious weight loss and other signs of systemic toxicity in the Waldenstrom macroglobulinemia (WM)-bearing mice.

VLX1570 inhibits USP14 and UCHL5 activity of 19S regulatory particles, and the inhibition of USP14 is more pronounced. VLX1570 (1 μM) shows inhibitory activity against USP14 in KMS-11 myeloma cells. VLX1570 exhibits an IC50 of 0.58 μM on HCT116 cells. VLX1570 binds to recombinant USP14 with Kd of 1.5-18?μM using two different sources of recombinant protein, and the Kd for recombinant UCHL5 is higher (14-18?μM) compared to that of USP14. VLX1570 has potent antiproliferative activities on multiple myeloma cells, with IC50s of 43?±?2 nM, 74?±?2 nM, 126?±?3 nM, and 191?±?1 nM for KMS-11, RPMI8226, OPM-2, and OPM-2-BZR cells, respectively. VLX1570 suppresses the viability of BCWM.1 cells, with an EC50 of 20.22?nM. VLX1570 (100, 250, 500 nM) induces significant apoptosis by 12?h in a dose-dependent manner in all Waldenstrom macroglobulinemia (WM) cell lines tested, including BCWM.1/IR (IR) and BCWM.1/BR (BR) subclones. VLX1570 (100, 250, 500 nM) also causes ER stress machinery and mitochondrial damage in WM cells. VLX1570 (250?nM) downregulates BCR-signalosome components and their end effectors, as well as CXCR4 expression in WM cells.

VLX1570 (3?mg/kg) significantly decreases tumor growth in mice bearing KMS-11 multiple myeloma cells. VLX1570 (4.4?mg/kg, i.p.) markedly suppresses tumor growth, without obvious weight loss and other signs of systemic toxicity in the Waldenstrom macroglobulinemia (WM)-bearing mice.

VLX 1570 | VLX-1570

Proteasome/Ubiquitin

DUB

DUB

Cancer

Blood cancer

1431280-51-1

469.3944

C23H17F2N3O6

>98% (HPLC)

DMSO: ≥ 32 mg/mL

O=C1/C(CN(C(C=C)=O)CC/C1=C/C2=CC=C(F)C([N+]([O-])=O)=C2)=C\C3=CC=C(F)C([N+]([O-])=O)=C3

4H-Azepin-4-one, 3,5-bis[(4-fluoro-3-nitrophenyl)methylene]hexahydro-1-(1-oxo-2-propen-1-yl)-

(-20℃)

With Ice Pack

≥ 2 years